+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Conjunctivitis - Pipeline Review, H1 2020

  • ID: 5007668
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 50 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adenovir Pharma AB
  • Invirsa Inc
  • IVIEW Therapeutics Inc
  • NanoViricides Inc
  • Okogen Inc
  • Panoptes Pharma GesmbH
  • MORE
Viral Conjunctivitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2020, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 5 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adenovir Pharma AB
  • Invirsa Inc
  • IVIEW Therapeutics Inc
  • NanoViricides Inc
  • Okogen Inc
  • Panoptes Pharma GesmbH
  • MORE
  • Introduction
  • Report Coverage
  • Viral Conjunctivitis - Overview
  • Viral Conjunctivitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Viral Conjunctivitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Viral Conjunctivitis - Companies Involved in Therapeutics Development
  • Adenovir Pharma AB
  • Invirsa Inc
  • IVIEW Therapeutics Inc
  • NanoViricides Inc
  • Okogen Inc
  • Panoptes Pharma GesmbH
  • Starpharma Holdings Ltd
  • TGV-Inhalonix Inc
  • Viral Conjunctivitis - Drug Profiles
  • APD-209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APD-514 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • astodrimer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EKCCide-I - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INV-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mul-1867 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • povidone iodine ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ranpirnase - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Viral Conjunctivitis - Dormant Projects
  • Viral Conjunctivitis - Discontinued Products
  • Viral Conjunctivitis - Product Development Milestones
  • Featured News & Press Releases
  • Dec 20, 2019: iView announces first patient treated in phase 2 clinical trial program evaluating IVIEW-1201 in patients with acute adenoviral conjunctivitis
  • Dec 27, 2018: US FDA requests further data for VivaGel BV approval
  • Dec 12, 2018: US patent granted for SPL7013 eye drops for conjunctivitis
  • Mar 06, 2017: iVIEW Therapeutics will present its novel sustained-release povidone iodine ophthalmic formulation for the treatment of acute conjunctivitis in TechConnect World Innovation Summit & Expo and US National Innovation Summit and National SBIR/STTR Conference
  • Sep 12, 2016: iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s National Eye Institute
  • May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
  • Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
  • Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Viral Conjunctivitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H1 2020
  • Viral Conjunctivitis - Pipeline by Invirsa Inc, H1 2020
  • Viral Conjunctivitis - Pipeline by IVIEW Therapeutics Inc, H1 2020
  • Viral Conjunctivitis - Pipeline by NanoViricides Inc, H1 2020
  • Viral Conjunctivitis - Pipeline by Okogen Inc, H1 2020
  • Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H1 2020
  • Viral Conjunctivitis - Pipeline by Starpharma Holdings Ltd, H1 2020
  • Viral Conjunctivitis - Pipeline by TGV-Inhalonix Inc, H1 2020
  • Viral Conjunctivitis - Dormant Projects, H1 2020
  • Viral Conjunctivitis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Viral Conjunctivitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adenovir Pharma AB
  • Invirsa Inc
  • IVIEW Therapeutics Inc
  • NanoViricides Inc
  • Okogen Inc
  • Panoptes Pharma GesmbH
  • Starpharma Holdings Ltd
  • TGV-Inhalonix Inc
Note: Product cover images may vary from those shown
Adroll
adroll